FLT3 and acute myeloid leukemia: Allogeneic SCT is an accepted standard of care in first CR, and based on several patient, AML and treatment-associated factors: (1) the presence of an adverse AML karyotype or high FLT3-mutated AR at diagnosis; (2) persistent MRD in CR; (3) low-risk of SCT-associated mortality based on the patient’s age and co-morbidities, donor availability and degree of matching.